ECSP088395A - Método de producción proteica utilizando compuestos anti-senescencia - Google Patents

Método de producción proteica utilizando compuestos anti-senescencia

Info

Publication number
ECSP088395A
ECSP088395A EC2008008395A ECSP088395A ECSP088395A EC SP088395 A ECSP088395 A EC SP088395A EC 2008008395 A EC2008008395 A EC 2008008395A EC SP088395 A ECSP088395 A EC SP088395A EC SP088395 A ECSP088395 A EC SP088395A
Authority
EC
Ecuador
Prior art keywords
cell culture
production method
protein production
senescence
senescence compound
Prior art date
Application number
EC2008008395A
Other languages
English (en)
Inventor
Denis Drapeau
Yen-Tung Luan
Wenge Wang
Paul Thoday
Judy Chou
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37873105&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP088395(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP088395A publication Critical patent/ECSP088395A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018Culture media for cell or tissue culture
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/30Organic components
    • C12N2500/32Amino acids
    • C12N2500/33Amino acids other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998Proteins not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells
    • C12N2510/02Cells for production

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)

Abstract

Se proporcionan métodos para producir una proteína en cultivo celular que comprende un compuesto anti-senescencia, tal como el antioxidante carnosina. De acuerdo con las enseñanzas de la presente invención, las células cultivadas en un medio de cultivo celular que comprende un compuesto anti-senescencia exhiben mayor viabilidad y productividad. Adicionalmente, los cultivos celulares cultivados en presencia de un compuesto anti-senescencia exhiben niveles reducidos de agregados de elevado peso molecular en el medio de cultivo celular.
EC2008008395A 2005-10-24 2008-04-23 Método de producción proteica utilizando compuestos anti-senescencia ECSP088395A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72957305P 2005-10-24 2005-10-24

Publications (1)

Publication Number Publication Date
ECSP088395A true ECSP088395A (es) 2008-05-30

Family

ID=37873105

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008395A ECSP088395A (es) 2005-10-24 2008-04-23 Método de producción proteica utilizando compuestos anti-senescencia

Country Status (24)

Country Link
US (1) US20070110743A1 (es)
EP (1) EP1941026B1 (es)
JP (2) JP2009512459A (es)
KR (1) KR101402634B1 (es)
CN (1) CN101297027B (es)
AR (1) AR058140A1 (es)
AU (1) AU2006306433B2 (es)
BR (1) BRPI0617744A2 (es)
CA (1) CA2627003C (es)
CR (1) CR9897A (es)
DK (1) DK1941026T3 (es)
EC (1) ECSP088395A (es)
ES (1) ES2485374T3 (es)
HK (1) HK1120552A1 (es)
IL (1) IL190550A (es)
NI (1) NI200800111A (es)
NO (1) NO20081622L (es)
PE (1) PE20070796A1 (es)
PL (1) PL1941026T3 (es)
PT (1) PT1941026E (es)
RU (1) RU2491347C2 (es)
SI (1) SI1941026T1 (es)
TW (1) TW200736397A (es)
WO (1) WO2007050498A2 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2495307T1 (en) 2006-07-13 2018-05-31 Wyeth Llc Production of the calibration factor IX with an improved glycolization pattern
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
MY185872A (en) 2006-09-13 2021-06-14 Abbvie Inc Cell culture improvements
TW200902708A (en) * 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
TWI610936B (zh) * 2008-10-20 2018-01-11 艾伯維有限公司 使用蛋白質a親和性層析進行抗體之分離及純化
MX2011004201A (es) 2008-10-20 2011-05-24 Abbott Lab Desactivacion viral durante purificacion de anticuerpos.
WO2011018472A2 (en) 2009-08-14 2011-02-17 Basf Se Methods in cell cultures, and related inventions, employing certain additives
US9012178B2 (en) 2010-08-05 2015-04-21 Amgen Inc. Dipeptides to enhance yield and viability from cell cultures
CN103097516B (zh) * 2010-08-31 2015-09-09 菲仕兰品牌公司 真核细胞培养基
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
TW201247874A (en) * 2011-05-25 2012-12-01 United Biomedical Inc Method for producing the activity of bone activating protein
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
SG11201504249XA (en) 2012-09-02 2015-07-30 Abbvie Inc Methods to control protein heterogeneity
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
AU2014229557B2 (en) * 2013-03-13 2017-12-07 Anteis Sa Peptides for skin rejuvenation and methods of using the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
AU2014233393B2 (en) * 2013-03-15 2020-05-28 Genentech, Inc. Cell culture compositions with antioxidants and methods for polypeptide production
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
WO2015057910A1 (en) 2013-10-16 2015-04-23 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
CN104398398A (zh) * 2014-10-27 2015-03-11 陈少威 一种细胞量子动力素(平衡剂)及其使用方法
MA40864A (fr) * 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
EP3247718B1 (en) 2015-01-21 2021-09-01 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
TWI797060B (zh) 2015-08-04 2023-04-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
US11401509B2 (en) 2015-11-09 2022-08-02 Bristol-Myers Squibb Company Methods of minimizing glycoprotein agregation in CHO cell production
WO2017120359A1 (en) * 2016-01-06 2017-07-13 Oncobiologics, Inc. Reduction of high molecular weight species, acidic charge species, and fragments in a monoclonal antibody composition
MX2018009341A (es) 2016-02-03 2019-05-15 Oncobiologics Inc Formulaciones tamponadas para una mayor estabilidad de anticuerpos.
AU2018350890A1 (en) * 2017-10-16 2020-03-19 Regeneron Pharmaceuticals, Inc. In situ Raman spectroscopy systems and methods for controlling process variables in cell cultures

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0939121B2 (de) * 1989-09-12 2007-12-26 AHP Manufacturing B.V. TFN-bindende Proteine
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE69132032T2 (de) * 1990-11-23 2000-12-21 Peptech Ltd Verzögerung, verhinderung und/oder rückgängigmachen von zellalterung
EP0940468A1 (en) * 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
RU2245365C2 (ru) * 1994-01-03 2005-01-27 Генентек Инк. Тромбопоэтин
US5830761A (en) * 1995-06-07 1998-11-03 Genetics Institute, Inc. Medium and methods for culturing mammalian cho cells
RU2134120C1 (ru) * 1995-06-26 1999-08-10 Безруков Михаил Васильевич Средство для стабилизации пептидной связи в белковом препарате
ATE219517T1 (de) * 1995-08-18 2002-07-15 Morphosys Ag Protein-/(poly)peptidbibliotheken
JP4306813B2 (ja) * 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
US6146847A (en) * 1996-11-01 2000-11-14 Genespan Corporation Stabilized transient gene expression
KR100942002B1 (ko) * 1996-12-03 2010-02-12 암젠 프레몬트 인코포레이티드 복수의 vh 및 vk 부위를 함유하는 사람 면역글로불린 유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된 항체
US20030040095A1 (en) * 2001-03-16 2003-02-27 Achille Arini Method for the production of pharmaceutically active recombinant proteins
AR035869A1 (es) * 2001-04-24 2004-07-21 Innogenetics Nv Proteinas de la envoltura de hcv glicosiladas en la estructura central, un metodo para producir la proteina de envoltura de hcv aislada, una composicion que la comprende, metodo para detectar la presencia de anticuerpos anti-hcv en una muestra, un kit de diagnostico para detectar la presencia de ant
JP4541157B2 (ja) * 2002-12-23 2010-09-08 ブリストル−マイヤーズ スクイブ カンパニー タンパク質を製造するための哺乳類細胞培養法
US9469672B2 (en) * 2003-10-27 2016-10-18 Wyeth Llc Removal of high molecular weight aggregates using hydroxyapatite chromatography
WO2005064013A1 (en) 2003-12-23 2005-07-14 Bart Janssen The use of carnosine metabolism-associated genes to determine genetic predisposition/susceptibility to diabetic nephropathy
US7294484B2 (en) * 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
US7300773B2 (en) * 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
TWI374935B (en) * 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
US7426440B2 (en) * 2004-09-24 2008-09-16 Nutritional Bioscience Ltd. Repair and protection factor scoring method for bioactive agents

Also Published As

Publication number Publication date
IL190550A (en) 2017-01-31
HK1120552A1 (en) 2009-04-03
RU2008113220A (ru) 2009-12-10
WO2007050498A2 (en) 2007-05-03
PE20070796A1 (es) 2007-08-15
AU2006306433A1 (en) 2007-05-03
CN101297027A (zh) 2008-10-29
CN101297027B (zh) 2013-04-03
WO2007050498A3 (en) 2007-07-12
JP2009512459A (ja) 2009-03-26
KR101402634B1 (ko) 2014-06-03
KR20080063365A (ko) 2008-07-03
EP1941026A2 (en) 2008-07-09
RU2491347C2 (ru) 2013-08-27
SI1941026T1 (sl) 2014-07-31
BRPI0617744A2 (pt) 2011-08-02
TW200736397A (en) 2007-10-01
CA2627003A1 (en) 2007-05-03
JP5907928B2 (ja) 2016-04-26
PL1941026T3 (pl) 2014-12-31
AR058140A1 (es) 2008-01-23
AU2006306433B2 (en) 2013-04-18
NI200800111A (es) 2009-03-03
NO20081622L (no) 2008-06-18
CA2627003C (en) 2018-08-28
EP1941026B1 (en) 2014-06-04
US20070110743A1 (en) 2007-05-17
DK1941026T3 (da) 2014-07-21
IL190550A0 (en) 2008-11-03
CR9897A (es) 2008-07-29
PT1941026E (pt) 2014-07-31
JP2013165728A (ja) 2013-08-29
ES2485374T3 (es) 2014-08-13

Similar Documents

Publication Publication Date Title
ECSP088395A (es) Método de producción proteica utilizando compuestos anti-senescencia
PA8778001A1 (es) Metodos de produccion de proteinas mediante la utilizacion de compuestos anti-senescencia
AU2019268194A1 (en) Cell culture system
AR090822A1 (es) Composiciones de cultivo de celulas y metodos para la produccion de polipeptidos
WO2008060541A3 (en) In vitro expansion of postpartum-derived cells using microcarriers
AR111785A2 (es) Método in vitro de producción de eritrocitos
CO6531436A2 (es) Métodos de producción de glucoproteínas en cultivos de celulas de mamiferos usando glucocorticoides
AR069956A1 (es) Procesos para cultivar celulas mamiferas secretoras de proteinas sanguineas heterologas
ATE540975T1 (de) Verbesserte faktor-viii-polypeptid-titer in zellkulturen
MX2019015525A (es) Modificacion genetica de ratas.
WO2011133902A3 (en) Cell culture medium comprising small peptides
BR112015023036A2 (pt) método para preparar um produto alcaloide benzilisoquinolina e célula microbiana engenheirada que produz um produto alcaloide benzilisoquinolina
AR109907A2 (es) Métodos para la producción de proteínas morfogenéticas óseas
CO6680636A2 (es) Método para producir adamts13 recombinante en cultivo celular
NO20072719L (no) Serumfritt cellekulturmedium for pattedyrceller
CR11827A (es) Activadores de glucoquinasa
MX356756B (es) Células madre pluripotentes en microportadores.
EP2588594A4 (en) METHODS FOR CULTURING INDIFFERENCED CELLS USING EXTENDED RELEASE COMPOSITIONS
WO2010048417A3 (en) Perfusion bioreactors, cell culture systems, and methods for production of cells and cell-derived products
BRPI0619579B8 (pt) Métodos para aumentar a expectativa de vida replicativa e/ou estabilidade de uma célula produtora de anticorpo, para expressar um gene de uma célula b codificando a cadeia pesada de ig e/ou cadeia leve de ig, para produzir linhagem de células b, para obter anticorpos, e, método ex vivo para produzir anticorpos capazes de especificamente ligar um antígeno de interesse
EA201170024A1 (ru) Способы получения высокой плотности жизнеспособных клеток в культуре клеток млекопитающих
SG10201809452RA (en) Cell culture compositions with antioxidants and methods for polypeptide production
BR112013028544A2 (pt) método para produzir um composto derivado de acetil-coa heterólogo
CR20160307A (es) Composiciones para la restauración de células y métodos para la preparación y utilización de las mismas
EA201170025A1 (ru) Способы повышения жизнеспособности и продукции культуры клеток